Guideline concordance in managing mHSPC [Video]

Hannah McManus, MD, Duke Cancer Institute, Duke University School of Medicine, Durham, NC, examines guideline-recommended treatment strategies for metastatic hormone-sensitive prostate cancer (mHSPC) in the US, focusing on changes over time. Data from the International Registry for Men with Advanced Prostate Cancer (IRONMAN) reveals high and stable rates of guideline-concordant first-line treatments, despite evolving therapies. Understanding the factors influencing treatment decisions is crucial for addressing disparities between guidelines and clinical practice in mHSPC management. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.